** Rhythm Pharmaceuticals RYTM.O said on Monday its drug Imcivree notably reduced weight in patients with a rare obesity disorder called hypothalamic obesity caused by damage to the brain, meeting the main goal of a late-stage trial
** Shares up 2.4% at 56.27 premarket
GLP-1 TREATMENTS INSUFFICIENT IN HO
** Stifel ("buy," PT: $78) says the efficacy of the drug is outstanding in a highly difficult-to-treat patient population and sees HO patient population as a blockbuster opportunity with the potential for a fast ramp
** Jefferies ("buy," PT: $80) says "other approved therapies and GLP-1s are clearly insufficient in addressing the underlying pathophysiology"
** TD Cowen ("buy," PT:$65) says the drug is setting up to be the new standard of care for the disease, adding the data should support approval
** TD Cowen projects Imcivree's revenue in HO will grow from $154 million in 2026 to $984 million in 2030
** H.C.Wainwright ("buy," PT:$80) says "key market opportunity now appears well within reach," adding Imcivree's pricing is expected to be the same as already-approved drugs
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.